Krista Rossi

Investigators conducted a post-hoc analysis in order to assess eosinophil levels and lung function among patients with low FEV1 reversibility to short-acting beta agonists.

Having asthma was associated with sensitization to 1 or more allergens. Having sensitization to the individual allergens—mouse, cockroach, and dust mite—were also associated with sensitization to 1 or more allergens.

Investigators also identified 3 distinct phenotypes that contribute to hospitalized patients with acute asthma exacerbation.

Investigators argued that reviews of healthcare interventions should include harmful side effects since they are essential to fully educate medical practice, health policies, and patients.

Although novel antibiotics has improved in the pipeline over the past 6 years, inadequacy behind the momentum in the development of new infection-fighting agents still remains.

The investigational agent being developed for the sleep-wake disorder demonstrated statistically significant improvements in the 6-month results.

Inner-city African-American patients are 5 times more likely to have hypertensive emergency, according to a recent study.

According to updated statistics form the American Heart Association (AHA), cardiovascular disease is present in approximately 50% of US adults.

The basis of a universal flu vaccine may be formed by antibodies that inhibit a second viral protein as well as the 1 that they bind.

The FDA has approved sumatriptan nasal spray (TOSYMRA, previously known as DFN-02) for the acute treatment of migraine with or without aura in adults.

Updates to the atrial fibrillation guidelines now recommend a newer type of blood-thinning medication called non-vitamin K oral anticoagulants (NOACs).

Investigators found atypical responses from brain cells known as astrocytes, which follow traumatic brain injuries (TBIs), may be the cause of epilepsy development.

Hilary Baldwin, MD, debunks the myths behind the nodular acne therapy she claims is a miracle drug.

The FDA has approved Janssen’s ibrutinib plus obinutuzumab for treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Investigators found the first evidence of a decline in type 1 diabetes incidence following implementation of the oral rotavirus vaccine into a routine immunization schedule.

While studies suggest buprenorphine may be the optimal pharmaceutical treatment for NAS, nonpharmacological approaches may be just as effective.

The FDA has approved trastuzumab-dttb (Ontruzant) for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma in combination with cisplatin and capecitabine or 5-fluorouracil.

The FDA has approved Verily’s Study Watch, a wearable medical device that conducts electrocardiograms (ECGs).

Increased opioid prescribing correlated with marketing opioid products to physicians, which subsequently correlated with an increase in mortality from overdoses.

The FDA Bone, Reproductive, and Urologic Drugs Advisory Committee voted in favor of approving romosozumab for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

The FDA has approved a scalpel-free method for the treatment of patients with Parkinson disease who experience tremors and are medication-resistant.

The FDA has approved cabozantinib (Cabometyx) for the treatment of patients with hepatocellular carcinoma who previously received sorafenib (Nexavar).

Dipanjan Basu, PhD, is testing non-melanoma drugs, like the investigational therapy omipalisib (GSK2126458) in cultured patient cells.

The rate of youths using flavored tobacco products increased by nearly 7% from 2016 to 2017.

The FDA has approved RFPi Inc’s blood flow and perfusion imaging medical device, iCertainty.

The FDA has approved EyeBOX, the first non-invasive, baseline-free tool directed at diagnosing concussions.

The study implies that B-cell depletion by rituximab therapy may be therapeutically beneficial in patients with secondary progressive multiple sclerosis.

The phase 3 CAMP-1 and CAMP-2 clinical trials evaluating VP-102 for the treatment of molluscum contagiosum demonstrated clinical and statistical significance.

The FDA has approved dasatinib (Sprycel) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Tardive dyskinesia made strides in 2018 with new and potential treatments as well as unearthed disease underpinnings.